Hence, the primary aim of the present study was to compare the effect of the mevalonate pathway intermediates on GFP-K-Ras protein dislocation in the pancreatic cancer cells treated with individual statins, and assess the role of these intermediates in the tumor-suppressive action of statins. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.